

Serial No. 10/613619

RECEIVED
CENTRAL FAX CENTER
JUL 28 2005

Remarks**DOUBLE PATENTING REJECTION**

The Office rejected claims 1, 3-7, 10-17, 21-24, and 34 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-26 of U.S. Patent No. 6,617,321 B2 in view of Martin et al. US 5,292,760.

While Applicants do not necessarily agree with the Office's assessment of the claims under the obviousness-type double patenting rejection, Applicants provide, only in order to expedite prosecution, a terminal disclaimer pursuant to 37 C.F.R. § 1.321. Applicants further submit that the filing of this terminal disclaimer is not an admission or acquiescence by, nor shall act as an estoppel upon, the Applicants on the merits of the rejection.

In view of the presently submitted terminal disclaimer, Applicants submit that claims 1, 3-7, 10-17, 21-24, and 34 are in condition for allowance. Reconsideration and withdrawal of the rejections is respectfully requested and allowance of claims 1, 3-7, 10-17, 21-24, and 34 is kindly solicited.

Respectfully submitted,



Nelsen L. Lentz
Attorney/Agent for Applicant(s)
Registration No. 38,537
Phone: 317-276-1207

Eli Lilly and Company
Patent Division/
P.O. Box 6288
Indianapolis, Indiana 46206-6288

July 28, 2005

Enclosure: Terminal Disclaimer
Extension for Reply within 1 month